On 31 August 2016 the autonomous Community of Madrid, Spain, reported two cases of infection with Crimean–Congo haemorrhagic fever (CCHF) virus. This document assesses the risk associated with the occurrence of two cases of Crimean–Congo haemorrhagic fever in Spain.
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
New and noteworthy in this update: the retrospective identification of novel coronavirus in biological samples from two fatal cases in Jordan (April 2012) and the results of a joint ECDC/WHO survey which confirms that EU/EEA Member States have an adequate capacity to detect novel coronavirus through their network of national reference laboratories: 18 of 30 in EU/EEA countries are capable of confirming positive screened samples by either ORF1b RT-PCR or other target RT-PCR assays with sequence analysis or whole-genome sequence analysis.
CDC updated risk assessment concludes that in the absence of evidence of sustained person-to-person transmission outside of household settings, the current facts still point towards a hypothesis of a zoonotic or environmental source with occasional transmission to exposed humans. WHO does not advise any travel or trade restrictions at this point for KSA or Qatar.
The purpose of this risk assessment is to evaluate the risk to the citizens of Europe of CPE spread through patient mobility and to assess the effectiveness of infection control methods to stop the spread of CPE within healthcare institutions.